Data reported for gefitinib use in Caucasian EGFR mutation-positive non-small-cell lung cancer patients

被引：0
|
作者：
Lake, Francesca
机构：
来源：
FUTURE ONCOLOGY | 2013年 / 9卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：930 / 930
页数：1
相关论文
共 50 条
  • [1] Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status
    Nakashima, Kazuhisa
    Kodama, Hiroaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Kawakado, Keita
    Yanagawa, Takashi
    Kitani, Kashu
    Hottta, Takamasa
    Abe, Masaaki
    Hamai, Kosuke
    Tanimoto, Takuya
    Ishikawa, Nobuhisa
    Tamura, Tomoki
    Kuyama, Shoichi
    Isobe, Takeshi
    Tsubata, Yukari
    RESPIRATORY INVESTIGATION, 2024, 62 (06) : 1137 - 1141
  • [2] Efficacy of afatinib following osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
    Tamura, Tomohiro
    Okubo, Hatsumi
    Yamada, Yutaka
    Kikkawa, Yasuko
    Yamaguchi, Shozaburo
    Hashimoto, Ikuta
    Kaburagi, Takayuki
    ANNALS OF ONCOLOGY, 2021, 32 : S335 - S335
  • [3] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Kobayashi, S
    Boggon, TJ
    Dayaram, T
    Janne, PA
    Kocher, O
    Meyerson, M
    Johnson, BE
    Eck, MJ
    Tenen, DG
    Halmos, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08): : 786 - 792
  • [4] FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Kazandjian, Dickran
    Blumenthal, Gideon M.
    Yuan, Weishi
    He, Kun
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1307 - 1312
  • [5] Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Funazo, T.
    Yasuda, Y.
    Hirai, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2416 - S2416
  • [6] First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
    Aix, Santiago Ponce
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Kenneth
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S203 - S204
  • [7] Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib
    Horn, Leora
    Gettinger, Scott
    Camidge, D. Ross
    Smit, Egbert F.
    Janjigian, Yelena Y.
    Miller, Vincent A.
    Pao, William
    Freiwald, Matthias
    Fan, Jean
    Wang, Bushi
    Chand, Vikram K.
    Groen, Harry J. M.
    LUNG CANCER, 2017, 113 : 51 - 58
  • [8] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
  • [9] Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study
    Abdullah, Matin Mellor
    Bhat, Amit
    Mohamed, Ahmad Kamal
    Ching, Foo Yoke
    Ahmed, Nida
    Gantotti, Sandeep
    ONCOLOGY LETTERS, 2016, 11 (04) : 2757 - 2762
  • [10] Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
    Lim, Sung Won
    Park, Sehhoon
    Kim, Youjin
    Cho, Jang Ho
    Park, Song Ee
    Lee, Hansang
    Kim, Hee Kyung
    Kim, Sung Min
    Sun, Jong Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    LUNG CANCER, 2018, 124 : 293 - 297
12345